Experimental drug aims to revive failing cancer fighters in rare sarcomas
Disease control
Recruiting now
This early-phase trial tests an immunotherapy drug called N-803 in up to 8 people with synovial sarcoma or myxoid/round cell liposarcoma whose cancer got worse after a prior cell therapy. N-803 is designed to boost the patient's own immune cells that survived the earlier treatmen…
Phase: EARLY_PHASE1 • Sponsor: Seth Pollack • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC